most recent survival rates for her2 positive breast cancer

Release time ：Dec-25,2024

Recent data indicates an enhancement in survival rates for patients with HER2-positive breast cancer. Typically, early detection and a multifaceted treatment approach are pivotal in enhancing these survival rates. In detail, for HER2-positive breast cancer patients, if the tumor is detected at an early stage and is subjected to targeted therapies including surgery, chemotherapy, radiotherapy, and HER2-directed treatments, the 5-year survival rate can exceed 90%. Conversely, if the disease has advanced or metastasized to distant regions, the survival rate can significantly decrease, with the 5-year survival rate potentially dropping to between 30% and 50%. Consequently, early identification and prompt treatment are of paramount importance for individuals with HER2-positive breast cancer. Additionally, patients should vigilantly monitor their health status, undergo regular follow-ups, and adhere to the prescribed standardized treatment regimen as directed by their physicians.